Search

La neuropatía periférica es un efecto secundario común de muchos tipos de quimioterapia. Obtenga información sobre qué es, por qué ocurre y cómo tratar la neuropatía periférica inducida por quimioterapia (CIPN).

… Tuesday, August 23, 2022 La neuropatía periférica , un trastorno nervioso que puede causar debilidad, entumecimiento, dolor y hormigueo o una sensación de “pinchazos”, es un efecto secundario común del tratamiento con quimioterapia . A veces descrita como “pies de quimioterapia” y “manos de quimioterapia

Hear from an MSK social worker about developing body confidence after cancer treatment.

… Wednesday, July 31, 2019 Summary A person’s body image can change during and after cancer treatment. But support is available. One MSK social worker shares common concerns and how people can find healing and hope. Even after the surgery is over, the last chemotherapy infusion has been given, and the

According to a new study published online today in the Journal of the National Cancer Institute, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.

… Tuesday, July 24, 2007 Steep Learning Curve Found According to a new study published online today in the Journal of the National Cancer Institute , prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by

In her 21 years at MSK, Tatanisha Peets has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services.

… Tuesday, February 22, 2022 In her 21 years at MSK,  Tatanisha Peets  has grown professionally and personally, working in Cytology, Pathology and now in Food and Nutrition services. Currently the Patient Experience Manager in Food and Nutrition Services, Tatanisha began her career at MSK as a secretary

Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, University of Washington School of Medicine, University of Michigan, and the Institute of Cancer Research Royal Marsden Hospital.

… Wednesday, July 6, 2016 Men with metastatic prostate cancer should be considered for germline genetic testing of DNA repair genes, regardless of age or family history, according to a team of researchers from Memorial Sloan Kettering Cancer Center (MSK), Fred Hutchinson Cancer Research Center, Dana-Farber

MSK’s SPORE grant in leukemia has the potential to develop practice-changing approaches, evaluation, and management that may lead to improved patient outcomes for AML.

… Tuesday, September 7, 2021 The National Cancer Institute (NCI) recently awarded Memorial Sloan Kettering Cancer Center (MSK) with a prestigious Specialized Programs of Research Excellence (SPORE) grant for leukemia research. The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone

Meet Leslie Ballantyne, Vice President of HR Legal and Regulatory Affairs at Memorial Sloan Kettering.

… Friday, April 2, 2021 Leslie Ballantyne says Eleanor Roosevelt has inspired her both personally and professionally. “The breadth of her accomplishments and commitment to her causes is just astounding,” says MSK’s Vice President of HR Legal and Regulatory Affairs. “She was ahead of her time in being an

A two-drug combination may hold the key to overcoming resistance in an aggressive form of non-Hodgkin lymphoma.

… Friday, November 16, 2018 Summary A promising target in the treatment of diffuse large B cell lymphoma (DLBCL) is a protein called BCL2. Drugs that inhibit this protein have been disappointing so far. Researchers have now discovered why DLBCL often proves resistant to this treatment. They have shown

A new era in the treatment of MIBC is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard of care in the perioperative treatment of cisplatin-ineligible or cisplatin-refusing patients. MSK’s David Aggen, MD, discusses this, and what new treatment approaches physicians and scientists at MSK are now testing.

… Thursday, November 13, 2025 A Q&A with  David Aggen, MD, PhD , MSK Genitourinary Medical Oncologist and Cellular Therapist A new era in the treatment of muscle-invasive bladder cancer (MIBC) is on the horizon, with the combination of enfortumab vedotin plus pembrolizumab poised to become the new standard

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.

… Friday, February 16, 2018 Summary As cancer is increasingly being brought under control in other parts of the body, there is a growing focus on treating tumors that spread to the brain. Metastatic brain cancer gets far less attention in the media than primary brain tumors , despite being at least ten